The biopharmaceutical landscape is undergoing a massive shift as targeted drug delivery moves from a promising concept to the primary standard of care. For decades, monoclonal antibodies served as the undisputed gold standard for targeted biological therapies, offering unprecedented precision in treating oncology, autoimmune diseases, and chronic inflammatory conditions. However, high...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
